当前位置：
X-MOL 学术
›
J. Natl. Cancer Inst.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2017-11-03 , DOI: 10.1093/jnci/djx226 Kathryn R Tringale 1 , Kate T Carroll 1 , Kaveh Zakeri 2 , Assuntina G Sacco 3 , Linda Barnachea 4 , James D Murphy 2
Journal of the National Cancer Institute ( IF 10.3 ) Pub Date : 2017-11-03 , DOI: 10.1093/jnci/djx226 Kathryn R Tringale 1 , Kate T Carroll 1 , Kaveh Zakeri 2 , Assuntina G Sacco 3 , Linda Barnachea 4 , James D Murphy 2
Affiliation
The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the treatment of HNC.
中文翻译：
Nivolumab治疗铂耐药的头颈部复发或转移性鳞状细胞癌的成本效益分析
CheckMate 141试验发现，nivolumab可以改善复发性或转移性头颈癌（HNC）患者的生存率。尽管生存期得到了改善，但nivolumab却比标准疗法昂贵得多。这项研究评估了nivolumab治疗HNC的成本效益。
更新日期：2018-05-14
中文翻译：
Nivolumab治疗铂耐药的头颈部复发或转移性鳞状细胞癌的成本效益分析
CheckMate 141试验发现，nivolumab可以改善复发性或转移性头颈癌（HNC）患者的生存率。尽管生存期得到了改善，但nivolumab却比标准疗法昂贵得多。这项研究评估了nivolumab治疗HNC的成本效益。
京公网安备 11010802027423号